A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Mar 2017
At a glance
- Drugs Durvalumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 10 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 17 Nov 2016 Planned number of patients changed from 208 to 264.
- 27 Sep 2016 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018.